This research study focuses on addressing the limitations of current neuropathic pain(NP)treatments by developing a novel dual-target modulator,E0199,targeting both Na_(V)1.7,Na_(V)1.8,and Na_(V)1.9 and K_(V)7 channel...This research study focuses on addressing the limitations of current neuropathic pain(NP)treatments by developing a novel dual-target modulator,E0199,targeting both Na_(V)1.7,Na_(V)1.8,and Na_(V)1.9 and K_(V)7 channels,a crucial regulator in controlling NP symptoms.The objective of the study was to synthesize a compound capable of modulating these channels to alleviate NP.Through an experimental design involving both in vitro and in vivo methods,E0199 was tested for its efficacy on ion channels and its therapeutic potential in a chronic constriction injury(CCI)mouse model.The results demonstrated that E0199 significantly inhibited Na_(V)1.7,Na_(V)1.8,and Na_(V)1.9 channels with a particularly low half maximal inhibitory concentration(IC50)for Na_(V)1.9 by promoting sodium channel inactivation,and also effectively increased K_(V)7.2/7.3,K_(V)7.2,and K_(V)7.5 channels,excluding K_(V)7.1 by promoting potassium channel activation.This dual action significantly reduced the excitability of dorsal root ganglion neurons and alleviated pain hypersensitivity in mice at low doses,indicating a potent analgesic effect without affecting heart and skeletal muscle ion channels critically.The safety of E0199 was supported by neurobehavioral evaluations.Conclusively,E0199 represents a ground-breaking approach in NP treatment,showcasing the potential of dual-target small-molecule compounds in providing a more effective and safe therapeutic option for NP.This study introduces a promising direction for the future development of NP therapeutics.展开更多
基金funded by the Key Project from the Hebei Provincial Department of Science and Technology,China(Grant No.:21372601D)the Foundation Postdoctoral Mobile Station of Basic Medical Sciences,Hebei Medical University,China(Grant No.:20123120019)+4 种基金the Natural Science Foundation of Hebei Province,China(Grant No.:H2021206352)the Science and Technology Research Project of Colleges and Universities in Hebei Province,China(Grant No.:QN2023197)Hebei Medical University,Science and Technology,China(Grant No.:CYQD2023014)Hebei Provincial Department of Human Resources and Social Security,China(Grant No.:B2023003034)the Consultative Foundation from Hebei Province,China(Grant No.:2020TXZH01).
文摘This research study focuses on addressing the limitations of current neuropathic pain(NP)treatments by developing a novel dual-target modulator,E0199,targeting both Na_(V)1.7,Na_(V)1.8,and Na_(V)1.9 and K_(V)7 channels,a crucial regulator in controlling NP symptoms.The objective of the study was to synthesize a compound capable of modulating these channels to alleviate NP.Through an experimental design involving both in vitro and in vivo methods,E0199 was tested for its efficacy on ion channels and its therapeutic potential in a chronic constriction injury(CCI)mouse model.The results demonstrated that E0199 significantly inhibited Na_(V)1.7,Na_(V)1.8,and Na_(V)1.9 channels with a particularly low half maximal inhibitory concentration(IC50)for Na_(V)1.9 by promoting sodium channel inactivation,and also effectively increased K_(V)7.2/7.3,K_(V)7.2,and K_(V)7.5 channels,excluding K_(V)7.1 by promoting potassium channel activation.This dual action significantly reduced the excitability of dorsal root ganglion neurons and alleviated pain hypersensitivity in mice at low doses,indicating a potent analgesic effect without affecting heart and skeletal muscle ion channels critically.The safety of E0199 was supported by neurobehavioral evaluations.Conclusively,E0199 represents a ground-breaking approach in NP treatment,showcasing the potential of dual-target small-molecule compounds in providing a more effective and safe therapeutic option for NP.This study introduces a promising direction for the future development of NP therapeutics.
